Connect public, paid and private patent data with Google Patents Public Datasets

Carvedilol

Info

Publication number
CA2413702A1
CA2413702A1 CA 2413702 CA2413702A CA2413702A1 CA 2413702 A1 CA2413702 A1 CA 2413702A1 CA 2413702 CA2413702 CA 2413702 CA 2413702 A CA2413702 A CA 2413702A CA 2413702 A1 CA2413702 A1 CA 2413702A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
carvedilol
form
solvent
crystalline
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2413702
Other languages
French (fr)
Inventor
Jean Hildesheim
Sergey Finogueev
Judith Aronhime
Ben-Zion Dolitzky
Shoshana Ben-Valid
Ilan Kor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceuticals Industries Ltd.
Jean Hildesheim
Sergey Finogueev
Judith Aronhime
Ben-Zion Dolitzky
Shoshana Ben-Valid
Ilan Kor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Abstract

This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.

Description

CARVEDILOL
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. provisional applications Nos.
60/214,356, filed June 28, 2000 and 60/246,358, filed Nov. 7, 2000, incorporated herein by reference.
FIELD OF THE INVENTION
This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.
BACKGROUND OF THE INVENTION
Carvedilol is a nonselective (3-adrenergic blocking agent with az blocking activity.
Carvedilol, also known as (~) 1-(9H-carbazol-4-yloxy)-3-[[2(2-methoxyphenoxy)ethyl]amino]-2-propanol, (CAS RegistryNo. 72956-09-3) has the structure of formula I.
~ ~ 0 O~N
H

N/
H
Carvedilol has a chiral center and can exist either as individual stereoisomers or in racemic form. Racemic carvedilol is the active ingredient of COREG~, which is indicated for the treatment of congestive heart failure and hypertension. The nonselective (3-adrenergic activity of carvedilol is present in the S(-) enantiomer and the a1 blocking activity is present in both the R(+) and S(-) enantiomers at equal potency. Both the racemate and stereoisomers may be obtained according to procedures well known in the art (EP B 0127 099).
Synthesis oaf Carvedilol U.S. Pat. No. 4,503,067, Which is incorporated herein by reference, discloses a process of preparing carvedilol by the following reaction:
o~
° ~°
H:N
H3C0°
N
H
II III
O~N
°
H

N
H
I5 in which 4-(oxiran-2-ylmethoxy)-9H-carbazole (formula II) is reacted with (2-(2-methoxyphenoxy)ethylamine (formula III) to form carvedilol (I). The above process produces a low yield of carvedilol at least in part because in addition to carvedilol, the process leads to the production of a bis impurity of the following structure (formula IV):

OH
\ /
N ~ N
H

O
OH
N
H
IV
(See EP 918055.) In order to reduce the formation of the formula IV and to increase the yield of carvedilol, EP 918055 discloses using a benzyl protected form of the 2-(2-methoxyphenoxy)ethylamine (III).
Caryedilol Polymorphs International application No. WO 99/05105, incorporated herein by reference, discloses that carvedilol can be isolated as two polymorphic forms, depending on the method of preparation. The two polymorphic forms, designated Form I and Form II, are reported to be monotropic and are distinguishable by their infrared, Rarnan and X-ray powder diffraction spectra. No evidence is found in the literature about the existence of hydrated solvate states of carvedilol.
Polymorphism is the property of some molecules and molecular complexes to assume more than one crystalline form in the solid state. A single molecule may give rise to a variety of crystal forms (also called "polymorphs", "hydrates" or "solvates") having distinct physical properties. For a general review of polymorphs and the pharmaceutical applications of polymorphs see G.M. Wall, Plaarm Manuf. 3, 33 (1986); J.K.
Haleblian and W. McCrone, J. Pharm. Sci., 58, 911 (1969); and J.K. Haleblian, J. Pharm.
Sci., 64, 1269 (1975), all of which are incorporated herein by reference.
The existence and physical properties of different crystal forms can be determined by a variety of techniques such as X-ray diffraction spectroscopy, differential scanning calorimetry and infrared spectroscopy. Differences in the physical properties of different crystal forms result from the orientation and intermolecular interactions of adj acent molecules (complexes) in the bulk solid. Accordingly, polymorphs, hydrates and solvates are distinct solids sharing the same molecular formula yet having distinct advantageous and/or disadvantageous physical properties compared to other forms in the polymorph family. The existence and physical properties of polymorphs, hydrates and solvates is unpredictable.
One of the most important physical properties of a pharmaceutical compound which can form polymorphs, hydrates or solvates, is its solubility in aqueous solution, particularly the solubility in gastric juices of a patient. Other important properties relate to the ease of processing the form into pharmaceutical dosages, such as the tendency of a powdered or granulated form to flow and the surface properties that determine whether crystals of the form will adhere to each other when compacted into a tablet.
SUMMARY OF THE INVENTION
The present invention provides a process for preparing carvedilol comprising a step of reacting a compound of formula II, 4-(oxiran-2-ylmethoxy)-9H-carbazole, o~

N
H
II
with a compound of formula III, 2-(2-methoxyphenoxy)ethylamine H,N
H3C0' III
wherein the compound of formula III is at a molar excess over the compound of formula II.
The present invention further provides crystalline carvedilol hydrate.
The present invention further provides crystalline carvedilol.
The present invention further provides crystalline carvedilol (methyl-ethyl-ketone) solvate.
The present invention further provides crystalline carvedilol Form III
characterized by an X-ray powder diffraction pattern having peaks at about 8.4 + 0.2, 17.4 ~ 0.2, and 22.0 ~ 0.2 degrees two-theta.
The present invention further provides crystalline carvedilol Form IV
characterized by an X-ray powder diffraction pattern having peaks at about 11.9 + 0.2, 14.2 + 0.2, 18.3 +
0.2, 19.2 + 0.2, 21.7 + 0.2, and 24.2 + 0.2 degrees two-theta.
The present invention further provides crystalline carvedilol (methyl-ethyl-ketone) solvate Form V characterized by an X-ray powder diffraction pattern having peaks at about 4.1 + 0.2, 10.3 + 0.2, and 10.7 + 0.2 degrees two-theta.
The present invention further provides carvedilol HCI Hydrate characterized by an X-ray powder diffraction pattern having peaks at about 6.5 + 0.2, 10.2 + 0.2, 10.4 + 0.2, 15.8 + 0.2,16.4 + 0.2 and 22.2+ 0.2 degrees two-theta.
The present invention further provides a method for preparing crystalline carvedilol Form I, comprising the steps of dissolving carvedilol in a solution by heating; heating the solution until the crystalline carvedilol is completely dissolved; reducing the temperature of the solution; agitating the solution for a period of time; further reducing the temperature of the solution; further agitating the solution for a period of time; and collecting crystalline carvedilol Form I.
The present invention further provides a method for preparing crystalline carvedilol Form II, comprising the steps of forming a solution of carvedilol by dissolving carvedilol in a solvent; precipitating carvedilol Form II by cooling the solution; and, isolating crystalline carvedilol Form II.
The present invention further provides a method for preparing crystalline carvedilol Form II, comprising the steps of forming a solution of carvedilol by dissolving carvedilol in a solvent mixture; precipitating carvedilol Form II by cooling the solution to about -20°C; and, isolating crystalline carvedilol Form II.
The present invention further provides a method for preparing crystalline carvedilol Form III, comprising the steps of dissolving carvedilol in a solvent to form a solvent solution; and, precipitating crystalline carvedilol Form III from the solvent solution using water as an anti-solvent.
The present invention further provides a method for preparing crystalline carvedilol Form III, comprising the steps of dissolving carvedilol in a solution by heating; cooling the solution mixture; and, collecting crystalline carvedilol Form III.
The present invention further provides a method for preparing crystalline carvedilol Form IV, comprising the steps of dissolving carvedilol in a solvent to form a solvent solution; adding an anti-solvent to the solvent solution; and, precipitating crystalline carvedilol Form IV from the solvent solution.
The present invention further provides a method for preparing crystalline carvedilol Form V, comprising the steps of dissolving carvedilol in a solvent to form a solvent solution; and, precipitating and isolating crystalline carvedilol Form V from the solvent solution.
The present invention further provides a method for preparing crystalline carvedilol Form V, comprising the steps of dissolving carvedilol in a solvent to form a solvent solution; and, precipitating and isolating crystalline carvedilol Form V from the solvent solution wherein the precipitation step is performed by adding an anti-solvent.
ERIEF DESCRIPTION OF THE FIGURES
Fig. 1. shows the X-ray diffraction pattern of carvedilol Form III.
Fig. 2. shows the DTG thermal profile of carvedilol Form III.

Fig. 3. shows the X-ray diffraction pattern of carvedilol Form IV.
Fig. 4. shows the DTG thermal profile of carvedilol Form IV.
Fig. 5. shows the X-ray diffraction pattern of carvedilol Form V.
Fig. 6. shows the DTG thermal profile of carvedilol Form V.
Fig. 7. shows the X-ray diffraction pattern of carvedilol HCl.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "carvedilol" includes hydrates and solvates of carvedilol.
The term "water content" refers to the content of water, based upon the Loss on Drying method (the "LOD" method) as described in Pharmacopeia Forum, Vol. 24, No. 1, p. 5438 (Jan - Feb 1998), the Karl Fisher assay for determining water content or thermogravimetric analysis (TGA). The term "equivalents of water" means molar equivalents of water. All percentages herein are by weight unless otherwise indicated. Those skilled in the art will also understand that the term "anhydrous", when used in reference to carvedilol, describes carvedilol which is substantially free of water. One skilled in the art will appreciate that the term "hemihydrate", when used in reference to carvedilol, describes a crystalline material having a water content of about 2.2% w/w. One skilled in the art will appreciate that the term "hydrate",in reference to carvedilol hydrochloride a crystalline material having a water content of about or above 2% w/w. One skilled in the art will also appreciate that the term "solvate of methyl-ethyl-ketone" refers to carvedilol in which solvent is contained within the crystal lattice in quantities above 1%. One skilled in the art will also appreciate that the term "solvate of methyl-ethyl-ketone" which contains one mole of is characterized by a methyl-ethyl-ketone content of about 14 % by weight.
Hydrate and solvate forms of carvedilol are novel and distinct from each other in terms of their characteristic powder X-ray diffraction patterns and their thermal profiles.
Fox the purposes of this specification, ambient temperature is from about 20°C to about 25°C.
All powder X-ray diffraction patterns were obtained by methods known in the art using a Philips X-ray powder diffractometer. Copper radiation of ~, = 1.5418 A
was used.
Measurement of thermal analysis are conducted for the purpose of evaluating the physical and chemical changes that may take place in a heated sample. Thermal reactions can be endothermic (e.g., melting, boiling, sublimation, vaporization, desolvation, solid-solid phase transitions, chemical degradation, etc.) or exothermic (e.g., crystallization, oxidative decomposition, etc.) in nature. Such methodology has gained widespread use in the pharmaceutical industry in characterization of polymorphism. Thermal measurements have proven to be useful in the characterization of polymorphic systems. The most commonly applied techniques are thermogravimetry (TGA), differential thermal analysis (DTA), and differential scanning calorimetry (DSC).
The DTA and TGA curves presented herein were obtained by methods known in the art using a DTG Shimadzu model DTG-50 (combined TGA and DTA). The weight of the samples was about 9 to about 13 mg. The samples were scanned up to about 300 ° C or above at a rate of 10°C/min. Samples were purged with nitrogen gas at a flow rate of 20 ml/min. Standard alumina crucibles covered lids with one hole.
Thermogravimetry analysis (TGA) is a measure of the thermally induced weight loss of a material as a function of the applied temperature. TGA is restricted to transitions that involve either a gain or a Loss of mass, and it is most commonly used to study desolvation processes and compound decomposition.
Karl Fisher analysis, which is well known in the art, is also used to determine the quantity of water in a sample.
As used herein, a solvent is any liquid substance capable of dissolving carvedilol.
As used herein, the term "anti-solvent" means a liquid in which a compound is poorly soluble. The addition of an anti-solvent to a solvent reduces the solubility of a compound.
As used herein a mixture of solvents refers to a composition comprising more than one solvent.
As used herein, the term "neat" conditions refers to conditions of a reaction wherein the solvent of the reaction is one of the reactants.
Syjzthesis oJf Carvedilol According to one embodiment, the present invention is a process for preparing carvedilol comprising a step of reacting a compound of formula II, 4-(oxiran-2-ylinethoxy)-9H-carbazole, o~

N
H
II
with a compound of formula III, 2-(2-methoxyphenoxy)ethylamine H,N

III.
The new procedure results in a higher yield of carvedilol than has been reported in the prior art. In addition, the product of the new procedure is nearly free of bis impurities and the reaction is more rapid.
Preferably, the compound of formula III is at a molar excess over the compound of formula II. The compound of formula III and the compound of formula II are preferably at a molar ratio from about 1.5:1 to about 100:1. More preferably, the compound of formula III and the compound of formula II are at a molar ration from about 2.8:1 to about 10:1.
Most preferably, the compound of formula III and the compound of formula II
are at a molar ratio from about 2.8:1 to about 6:1.
In one embodiment of the present invention, the reacting step is performed in a solvent. The solvent is preferably selected from the group consisting of toluene, xylene and heptane. In an alternative embodiment, the reacting step is performed in a solvent mixture wherein the solvent mixture comprises multiple solvents. Preferably, a solvent of the solvent mixture is selected from the group consisting of toluene, xylene and heptane.
The reacting step is preferably performed at a temperature from about 25°C and about 150°C. Most preferably, the reacting step is performed at a temperature from about 60°C and about 120°C.
In an alternative embodiment, the reacting step is performed under neat conditions.
The neat conditions may obtained by melting a solid form of the compound of formula III
to form a liquid and, dissolving the compound of formula II in the liquid to form a reaction mixture.
The reaction performed under neat conditions may further comprise a step of reducing the temperature of the reaction mixture after dissolving the compound of formula II. The temperature is preferably reduced to about 70°C.
The reaction performed under neat conditions may further comprise a step of adding an organic solvent: water mixture to the reaction mixture. The organic solvent is preferably selected from the group consisting of ethyl acetate, methyl isobutyl ketone, methyl ethyl ketone and butyl acetate.
The reaction performed under neat conditions may further comprise a step of adjusting the pH of the organic solvent: water mixture after it is added to the reaction mixture. The pH is preferably adjusted to less than about pH 5. More preferably, the pH is adjusted from about pH 3 to about pH 5.
Optionally, the process further comprises the steps of isolating carvedilol hydrochloride after adjusting the pH, and purifying carvedilol.
Carvedilol hydrochloride is optionally isolated as a hydrate. Carvedilol HCl isolated as a hydrate typically has an XRD peaks are found at about 6.5 + 0.2, 10.2 + 0.2, 10.4+0.2, 14.2+0.2, 14.7+0.2, 16.4+0.2, 17.7+0.2,20.0+0.2,21.9+0.2,25.2+0.2 degrees to 2-theta.
The reaction preformed under neat conditions may further comprise steps of, isolating carvedilol from the reaction mixture after adjusting the pH, and purifying carvedilol. Optionally, carvedilol may be purified by methods well known in the art. (See EP B 0127 099.) Novel Metlzods,for Preparih~ Crystalline Carvedilol Form I ahd Form II
One aspect of the present invention provides a method for preparing crystalline carvedilol Form I, by dissolving carvedilol in a solvent until the crystalline carvedilol is completely dissolved, reducing the temperature of the solution and agitating the solution for a period of time, further reducing the temperature of the solution and agitating the solution for a period of time and, collecting crystalline carvedilol Form I.
The dissolving step is optionally performed by heating the solvent.
The dissolving step is optionally performed by heating crystalline carvedilol at a S temperature from about SO° C 0 to about 60° C for about 6 hours.
The dissolving step is optionally performed by suspending the crystalline carvedilol in ethyl acetate.
The dissolving step is optionally performed by heating the solution to about 77°C.
The step of reducing the temperature of the solution is optionally performed by cooling the solution to about SO° C in a time period of 1 S min.
The step of agitating solution is optionally performed at about SO° C
for about 48 hours.
The step of further reducing the temperature of the solution is optionally performed by cooling the solution to about 10°C in about 0.75 hours with agitation.
1 S The step of further agitating the solution is optionally performed by stirring the suspension for more than S hours. The step of further agitation may optionally be performed by stirring the suspension for about 24 hours.
The drying step may be performed by heating crystalline carvedilol at a temperature from about SO° C 0 to about 60° C for about 6 hours.
The suspending step may be performed by suspending the crystalline carvedilol in ethyl acetate.
The heating step may be performed by heating the solution to about 77°C.
Another aspect of the present invention provides a method for preparing crystalline carvedilol Form II, comprising the steps of forming a solution of carvedilol by dissolving 2S carvedilol in a solvent, precipitating carvedilol Form II by cooling the solution, and isolating crystalline carvedilol Form II.
Optionally, the step of dissolving carvedilol is performed at a temperature from about 40° C to about the boiling temp of the solvent.
Optionally, the step of cooling the solution is performed by reducing the temperature from about -20 °C to about ambient temperature.

Optionally, the solvent is selected from the group consisting of methanol, absolute ethanol, 1-propanol, isopropanol, n-butanol, ethylene glycol, butyl acetate, isobutyl methyl ketone, dichloromethane, dichloroethane, acetonitrile, acetone, isoamylalcohol, xylene and toluene.
Optionally, the precipitated carvedilol Form II is isolated by filtration.
Another aspect of the present invention provides a method for preparing crystalline carvedilol Form II, comprising the steps of forming a solution of carvedilol by dissolving carvedilol in a solvent mixture, precipitating carvedilol Form II by cooling the solution to about -20°C, and isolating crystalline carvedilol Form II.
Optionally, the carvedilol is dissolved in a solution at a temperature from about 40°C to about the boiling temperature of the solvent.
Optionally, the carvedilol Form II is isolated by filtration.
Optionally, the step of cooling the reaction is performed by cooling the solution to a temperature from about -20°C to ambient temperature.
Optionally, the solvent mixture is selected from the group consisting of acetone:
cyclohexane, chloroform: cyclohexane, dichloroethane: cyclohexane, dichloromethane:
cyclohexane, pyridine: cyclohexane, tetrahydrofurane:cyclohexane, dioxane:
cyclohexane, acetone: hexane, chloroform: hexane, dichloroethane: hexane, dichloromethane:
hexane, tetrahydrofuran: hexane and ethanol: hexane.
Novel Carvedilol Polvnaor~hs In another aspect the present invention provides new crystalline forms of carvedilol, designated Forms III, IV, V and processes for the manufacture thereof.
Moreover, the present invention provides a new hydrate form of carvedilol, having water content of about 2 % by weight and processes for their manufacture. In another embodiment, the present invention provides new solvate forms of carvedilol, having solvent content up to about 14 by weight, wherein the solvent is methyl ethyl ketone, and processes for their manufacture. These hydrate/ solvate forms of carvedilol are useful as intermediates for the synthesis of carvedilol drug substances.
Procedures for Crystallizifig Novel Forms of Carvedilol The novel hydrates/solvates forms provided herein axe optionally formed by precipitating carvedilol as a crystalline solid from a solvent or a solvent mixture. It will be understood by those of skill in the art, that other methods may also be used to form the hydrate/solvates form disclosed herein. Alternatively the polymorphs may be formed by routine modification of the procedures disclosed herein.
Formation of Crystalline Canvedilol Form III.
One embodiment of the present invention provides a method for preparing crystalline carvedilol Form III, which comprises the steps of forming a solvent solution containing carvedilol; and, precipitating crystalline carvedilol Form III from the solvent solution using water as an anti-solvent. The invention provides for a dissolving step wherein water is present in the solvent solution during the dissolving step.
The invention also provides for a precipitation step wherein water is added to the solution after carvedilol is fully dissolved in a solvent.
Optionally, to form the solvent solution containing carvedilol, carvedilol may be dissolved in a solvent at elevated temperature. The preferred elevated temperature is from about 40 to about 90 °C. Most preferably the elevated temperature is about 55 °C.
Alternatively, carvedilol may be dissolved in a solvent at ambient temperature.
Another embodiment of the present invention provides, forming the solvent solution containing carvedilol, by dissolving carvedilol in a solvent and inducing precipitation of crystalline carvedilol Form III by the addition of an anti-solvent. Solvents are optionally selected from the group which includes pyridine, dioxane, isopropanol and chloroform. Anti-solvents are optionally selected from the group which includes water and hexane.
An alternative embodiment of the present invention provides, forming the solvent solution containing carvedilol by dissolving carvedilol in an organic solvent and water and precipitating crystalline carvedilol Form III. In this embodiment the organic solvent is optionally an alcohol. The alcohol is preferably selected from the group consisting of methanol and ethanol. Alternatively, the organic solvent may be selected from the group of solvents consisting of pyridine, dioxane, and ethyl acetate and tetrahydrofurane.
An alternative embodiment of the present invention provides, a method for preparing crystalline carvedilol Form III, comprising the steps of drying crystalline carvedilol at elevated temperature, suspending crystalline carvedilol in a solution mixture, heating the solution mixture until the crystalline carvedilol is completely dissolved, cooling the solution mixture, and collecting crystalline carvedilol Form III.
Optionally, the drying step may be performed by heating crystalline carvedilol at a temperature from about 50° C to about 60° C for about 6 hours.
Optionally, the suspending step may be performed by suspending the crystalline carvedilol in a solution mixture of ethyl acetate: water (150:40).
Optionally, the heating step may be performed by heating the solution mixture from about 60 to about 70°C with agitation until the crystalline carvedilol is completely dissolved.
Optionally, the cooling step may be performed by cooling the solution mixture to about to 10° C for a period of about 3 hours with agitation.
Formation of Crystalline Carvedilol Form ITS
The present invention also provides a method for preparing crystalline carvedilol Form IV by forming a solvent solution containing carvedilol and inducing precipitation of crystalline carvedilol Form IV by the addition of an "anti-solvent". In this embodiment, solvents are optionally selected from the group which includes methyl ethyl ketone, and a methyl isobutyl ketone. Anti-solvents are optionally selected from the group which includes cylcohexane and heptane.
Optionally, to form crystalline carvedilol Form IV carvedilol may be dissolved in a solvent at from below ambient temperature to elevated temperatures. The preferred temperature is from about 10° to about 50°C. Most preferably the temperature is ambient temperature.
Formation of Crystalline Carvedilol Form V.
1 The present invention also provides a method for preparing crystalline carvedilol Form V by forming a solvent solution containing carvedilol and inducing precipitation of crystalline carvedilol solvate Form V by cooling or by adding an anti-solvent.
In this embodiment, the solvent is optionally selected from the group which includes methyl ethyl ketone. Anti-solvents are optionally selected from the group which includes cylcohexane and hexane.

Optionally, to form crystalline carvedilol Form V the carvedilol may be dissolved in a solvent solution at elevated temperature. The preferred elevated temperature is from about 10 to about 80° C. Most preferably the elevated temperature is about 55° C.
Alternatively, carvedilol may be dissolved in a solvent solution at ambient temperature.
Novel Hvdrate ahd Solvate Crystal Forms of Carvedilol The present invention provides novel crystal forms of carvedilol which will be designated as Forms III, IV and V, as well as carvedilol HCl. These forms can be distinguished from the prior art forms of carvedilol and from each other by characteristic powder X-ray diffraction patterns and thermal profiles.
The different crystal forms may also be characterized by their respective solvation state. The most commonly encountered solvates among pharmaceuticals are those of 1:1 stoichiometry. Occasionally mixed solvate species are encountered. When water or solvent is incorporated into the crystal lattice of a compound in stoichiometric proportions, the molecular adduct or adducts formed are referred to as hydrates or solvates.
' Crystalline Carvedilol Form III
Carvedilol Form III ("Form III") is characterized by an X-ray diffraction pattern with peaks at about 8.4 + 0.2, 9.3 + 0.2, 11.6 + 0.2, 13.2 + 0.2, 13.5 + 0.2, 14.2 + 0.2, 15.3 +0.2, 15.8+0.2,17.4+0.2, 18.4+0.2, 19.4+0.2,20.6+0.2,21.4+0.2,22.0+0.2,26.5 + 0.2 and 27.6 + 0.2 degrees two-theta. The most characteristic peaks of Form III are at about 8.4 + 0.2, I7.4 + 0.2, and 22.0 + 0.2 degrees two-theta. The diffraction pattern is reproduced in Fig. 1.
The DTG thermal profile of Form IV is shown in Fig. 2. The differential scanning calorimetry (DSC) thermal profile of form III shows one melting peak around 100°C
(96°C - 110°C), depending on the samples and on the particle size. This melting peak is concomitant to a loss on drying of about 2% as measured by thermal gravimetric analysis (TGA). The amount of water in the sample as determined by Karl Fisher analysis is in good agreement with the value obtained from TGA, thus confirming that the loss on drying is due to the dehydration of water, and indicating that this material is a.

Crystalline Ca~vedilol Form ITl Carvedilol Form IV ("Form IV") is characterized by an X-ray diffraction pattern with peaks at about 11.9 + 0.2, 14.2 + 0.2, 15.7 + 0.2, 16.5 + 0.2, 17.7 +
0.2, 18.3 + 0.2, 19.2+0.2,19.6+0.2,21.7+0.2, 22.2+0.2,23.9+0.2,24.2+0.2,24.9+0.2,27.4+0.2 and 28.2 + 0.2 degrees two-theta. The most characteristic peaks of Form IV are at about 11.9 + 0.2, 14.2 + 0.2, 18.3 + 0.2, 19.2 + 0.2, 21.7 + 0.2, and 24.2 + 0.2 degrees two-theta.
The diffraction pattern is reproduced in Fig. 3.
The DTG thermal profile of Form IV is shown in Fig. 4. The DSC thermal profile of form IV shows one melting peak at about 104 ° C.
Crystalline Catwedilol Form h Carvedilol Form V ("Form V") is characterized by an X-ray diffraction pattern with peaks at about 4.1 + 0.2, 10.3 + 0.2, 10.7 + 0.2, 11.5 + 0.2, 12.6 + 0.2, 14.0 + 0.2, 14.8+0.2, 15.4+0.2, 16.4+0.2, 16.8+0.2, 18.8+0.2,20.8+0.2,21.1+0.2,21.6+0.2, and 25.4 + 0.2, degrees two-theta. The most characteristic peaks of Form IV
are at about 4.1 + 0.2, 10.3 + 0.2, 10.7 + 0.2 and 11.5 + 0.2 degrees two-theta. The diffraction pattern is reproduced in Fig. 5.
The DTG thermal profile of Form V is shown in Fig. 6. The DSC thermal profile of Form V shows a solvent desorption endotherm. at about 67°C, followed by a recrystallization event, and a melting peak at 115 ° C. The desorption endotherm is concomitant to a loss on drying of about 14% as determined by TGA. This behavior is consistent with the loss of a molecule of MEK per molecule of carvedilol (the calculated stoichiometric value of mono-MEK is 15%).
Carvedilol HCZ Hydrate Crystalline Carvedilol HCl is characterized by an X-ray diffraction pattern with peaks atabout6.5~0.2, 10.2~0.2, 10.4~0.2, 14.2~0.2, 14.7+0.2, 15.8+0.2, 16.4+0.2, 17.7~0.2,20.0~0.2,21.5~0.2,21.9+0.2,22.2+0.2,22.9+0.2,25.2+0.2,25.3+0.2, 27.2 + 0.2, 27.4 + 0.2, 28.2 + 0.2, 28.6 + 0.2, 29.6 + 0.2 degrees two theta.
The most characteristic peaks of crystalline carvedilol HCl are at about 6.5 + 0.2, 10.2 + 0.2, 10.4 +

0.2,15.8 + 0.2,16.4 + 0.2 and 22.2+ 0.2 degrees two-theta. The diffraction pattern is reproduced in Fig. 7.
The DTG thermal profile of carvedilol HCl shows two endothermic peaks. A peak at 118°C is a dehydration peak. A second peak endothermic peak at 13S°C is due to S melting of the sample. LOD for this sample is 3.S%. The Water content of this sample as measured by Karl-Fisher analysis is 3.7%. Thus the Karl-Fisher analysis is in agreement with LOD value, and confirm the presence of hydrate in this sample. The expected value for carvedilol HCl monohydrate is 3.9 A Pharmaceutical Compositiofz Contaihihg Carvedilol According to another aspect, the present invention relates to a pharmaceutical composition comprising one or more of the novel crystal forms of carvedilol disclosed herein and at least one pharmaceutically acceptable excipient. Such pharmaceutical compositions may be administered to a mammalian patient in a dosage form.
The dosage forms may contain one or more of the novel forms of carvedilol or, 1 S alternatively, may contain one or more of the novel forms of carvedilol as part of a composition. Whether administered in pure form or in a composition, the carvedilol forms) may be in the form of a powder, granules, aggregates or any other solid form. The compositions of the present invention include compositions for tableting.
Tableting compositions may have few or many components depending upon the tableting method used, the release rate desired and other factors. For example, compositions of the present invention may contain diluents such as cellulose-derived materials like powdered cellulose, microcrystalline cellulose, microfine cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose salts and other substituted and unsubstituted celluloses; starch;
2S pregelatinized starch; inorganic diluents such calcium carbonate and calcium diphosphate and other diluents known to one of ordinary skill in the art. Yet other suitable diluents include waxes, sugars (e.g. lactose) and sugar alcohols like mannitol and sorbitol, acrylate polymers and copolymers, as well as pectin, dextrin and gelatin.
Other excipients contemplated by the present invention include binders, such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes; disintegrants such as sodium starch glycolate, crospovidone, low-substituted hydroxypropyl cellulose and others; lubricants like magnesium and calcium stearate and sodium stearyl fumarate;
flavorings; sweeteners; preservatives; pharmaceutically acceptable dyes and glidants such as silicon dioxide.
Dosage forms may be adapted for administration to the patient by oral, buccal, parenteral, ophthalmic, rectal and transdermal routes. Oral dosage forms include tablets, pills, capsules, troches, sachets, suspensions, powders, lozenges, elixirs and the like. The novel forms of carvedilol disclosed herein also may be administered as suppositories, ophthalmic ointments and suspensions, and parenteral suspensions, which are administered by other routes. The most preferred route of administration of the carvedilol forms of the present invention is oral.
Capsule dosages will contain the solid composition within a capsule which may be coated with gelatin. Tablets and powders may also be coated with an enteric coating. The enteric-coated powder forms may have coatings comprising phthalic acid cellulose acetate, hydroxypropylmethyl cellulose phthalate, polyvinyl alcohol phthalate, carboxymethylethylcellulose, a copolymer of styrene and malefic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, they may be employed with suitable plasticizers andlor extending agents. A coated tablet may have a coating on the surface of the tablet or may be a tablet comprising a powder or granules with an enteric-coating.
The currently marketed form of carvedilol is available as a 3.125 mg, a 6.25 mg, a 12.5 mg, and a 25 mg tablet which includes the following inactive ingredients:
colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyethylene glycol, polysorbate 80, povidone, sucrose, and titanium dioxide.
The function and advantage of these and other embodiments of the present invention will be more fully understood from the examples below. The following examples are intended to illustrate the benefits of the present invention, but do not exemplify the full scope of the invention.

EXAMPLES
Example 1:
Preparation of Carvedilol in neat conditions.
2-(2-Methoxyphenoxy)ethylamine (III) (4.89 g) was heated to about 100°C, after which 4-(oxiran-2-ylmethoxy)-9H-carbazole (II) (3.31 g) was added portionwise.
After approximately 20 minutes, the reaction mixture was cooled to about 70°C, after which water (25 ml) and ethyl acetate (15 ml) were added. The pH of the two-phase mixture was then adjusted to 5 with 2 N hydrochloric acid. The solid that formed, Carvedilol hydrochloride hydrate, is filtered, washed with water (20m1) followed with ethylacetate (15m1).
The resulting material is reslurried in ethylacetate (SOml) and water (20m1) containing 5%
Sodium carbonate until the pH reached 7.5. The organic phase was separated and dried over sodium sulfate. The dried solution was concentrated to a turbid solution and cooled overnight to about 4oC. Precipitated carvedilol was isolated by filteration and crystallized from isopropanol.
Example 2:
Preparation of Carvedilol in neat conditions.
2-(2-Methoxyphenoxy)ethylamine (III) (4.89 g) was heated to about 100°C, after which 4-(oxiran-2-ylmethoxy)-9H-carbazole (II) (3.31 g) was added portionwise.
After approximately 20 minutes, the reaction mixture was cooled to about 70°C, after which water (25 ml) and ethyl acetate (1 S ml) were added. The pH of the two-phase mixture was then adjusted to 5 with 2 N hydrochloric acid. The solid that formed, Carvedilol hydrochloride hydrate, is filtered, washed with water (20m1) followed with ethylacetate (15m1).
The resulting material is reslurried in ethylacetate (SOmI) and water (20m1) containing 5% Sodium carbonate until the pH reached 7.5. The organic phase was separated and dried over sodium sulfate. The dried solution was concentrated to a turbid solution and cooled overnight to about 4°C. Precipitated carvedilol was isolated by filteration and crystallized from methanol.

Example 3:
Process for preparing Form I of Carvedilol Crystalline carvedilol is prepared according to the procedure in Example 3.
The crystalline material is then dried at 50-60°C for 6 hours. The dried crystalline carvedilol (220 g carvedilol) is dissolved in 2200 ml Ehtyl Acetate. The ethyl acetate solution is heated with agitation to 77°C until the solid is completly dissolved.
The ethyl acetate solution was then cooled with agitation to about 50°C in a time period of 15 min. Te cooled solution was stirred for 48 hours. The solution was then cooled to 10°C in 0.75 hours with agitation. After stirring the suspension for additional 24 hours, the product was filtered. Pure Crystalline carvedilol Form I (170 g) was obtained.
Example 4:
Preparation of Crystalline Carvedilol Form II .
Crystalline carvedilol Form II is formed by crystallizing carvedilol from the solvents listed in Table I. Carvedilol is crystallized by forming a solution of carvidilol heated to reach a clear solution, usually close to the solvent boiling temperature. The solution is then cooled to ambient temperature and the precipitate is filtered to yield Carvedilol for II.

Table I
Solvent Ratio of Solvent (ml) : Carvedilol (g) Methanol 11 Ethanol abs. 12 1-propanol 14 Isopropanol 13 n-Butanol 11 Ethylen glycol13 Ethyl-acetate 10 Butyl Acetate 12 isobutyl methl12 ketone Dichloromethane12 Dichloroethane25 Acetonitile 50 Acetone 25 Example 5:
Preparation of Crystalline Carvedilol Form II by Filtration at -20 °C.
Crystalline carvedilol Form II is formed by crystallizing carvedilol from the solvents listed in Table II. Carvedilol is crystallized by forming a solution of carvidilol heated to about the solvent boiling temperature. The solution is then cooled to -20 °C, the precipitate is filtered and dried to yield Carvedilol Form II.

Table II
Solvent Ratio of Solvent (ml) Carvedilol (g) [Please Confirm Units]

Isoamylalcohol50 Toluene 53 Xylene I 51 Example 6:
Preparation of Crystalline Carvedilol Form II in Solvent Mixtures Crystalline carvedilol Form II is formed by crystallizing carvedilol from the mixture of solvents listed in Table III. Carvedilol is crystallized by forming a solution of carvidilol heated to form a clear solution, usually close to the boiling temperature of the mixture of solvent. The solution is then cooled to ambient temperature and filtered. The crystals are collected by filtration and dried to yeld Carvedilol form II.

Table III
Solvent Solvents Ratio Solvent ratio (ml) Carvedilol (g) [Please Confirm Units]

Acetone : 1:4.8 230 S Cyclohexane Chloroform: 1:3 130 Cyclohexane Dichloroethane:1:2.5 142 cyclohexane Dichloromethane:1:1.7 90 Cyclohexane Pyridine: 1:3.5 45 Cyclohexane Tetrahydrofurane1:2.5 53 :Cyclohexane Dioxane: 1:2.3 70 Cyclohexane Acetone: Hexane1:2 235 Chloroform: 1:1.5 87 hexane Dichloroethane:1:1.2 89 Hexane Dichloromethane:1:1.6 90 hexane Tetrahydrofuran:1:3 49 Hexane Ethanol: Hexane1:3.8 I45 Example 7:
Preparation of Crystalline Carvedilol Form III .
Carvedilol (4g) was dissolved in 45mL of a mixture of 96% Ethanol and 4% water by heating the mixture under stirring in a 55 ° C water bath. The solution was cooled and left at room temperature without stirring for about 14 hours, the crystals were filtered through a buchner funnel, rinsed twice with about lOml cold (4°C) 96%
ethanol, and dried in a desiccator at room temperature (connected to air pump) until constant weight to yield carvedilol Form III.
Example 8:
Preparation of Crystalline CarvediloI Form III.
Carvedilol (4g) was dissolved in 195mL mixture of water/methanol (in a ratio 1:3 respectively ) by heating the mixture under stirnng in 55 °C water bath. The solution cooled to ambient temperature and left at ambient temperature without stirnng for about 15h, the crystals were filtered through a buchner and dried in a desiccator at room temperature (connected to air pump) until constant weight to yield carvedilol Foam III.
Exam 1u a 9:
Preparation of Crystalline CarvediloI Form III, Carvedilol (4g) was dissolved in 39mL pyridine by stirring at room temperature.
70mL of water was then added dropwise until crystallization began. The solution was left at room temperature without stirring for about SOh, then the crystals were filtered through a buchner and dried in a desiccator at room temperature (connected to air pump) until constant weight to yield Carvedilol Form III.
Exam 1u a 10:
Preparation of Crystalline Carvedilol Form III
Carvedilol (4g) was dissolved in 76 mL dioxane at room temperature, and 110 mL
of water were added in portions of about 10 mL to the stirred solution. The resulting solution was left at room temperature without stirring for about 15h, then the crystalline precipitate which had formed was filtered through a buchner funnel and dried in desiccator at room temperature (connected to air pump) until constant weight to yield Carvedilol Form III in a mixture with Carvedilol Form II.
Example 11:
Preparation of Crystalline Carvedilol Form III
Carvedilol (4g) was dissolved in 267mL dioxane/water in the ratio 1:1.4 respectively by heating the mixture under stirring at 55 °C water bath.
The resulting solution was left at room temperature without stirring for about 15h then the crystals were filtered through a buchner funnel and dried in a desiccator (connected to air pump) until constant weight to yield Carvedilol Form III in a mixture with Carvedilol Form II.

Exam 1u a 12:
Preparation of Crystalline Carvedilol Form III
Carvedilol (4g) was dissolved in 180m1, Hexane/IPA in a ratio 1: 1 by heating the mixture under stirring at 55 °C water bath. The solution was allowed to sit at room temperature without stirnng for about 15h, then the resulting crystals were filtered through a buchner funnel and dried in a desiccator (connected to air pump) at room temperature until constant weight to yield Carvedilol Form III.
Example 13:
Process for preparing Form III of Carvedilol I O Carvedilol (40 g) was dissolved in 150 mI of ethanol and 40 ml water. The solution was heated with agitation to 60-70°C until the solid material was completely dissolved.
The solution is then cooled with agitation to 10° C over a period of 3 hours. After stirring the suspension for an additional 2.75 hours, the product is filtered. Pure Carvedilol Form III (35 g) was obtained.
Example 14:
Preparation of Crystalline Carvedilol Form IV .
Carvedilol (1g) was dissolved in 35 mL methyl ethyl ketone by stirnng at room temperature, and 202 mL cyclohexane was added dropwise. The solution was left at room temperature without stirring for about 15h, then the resulting crystals were filtered through a buchner funnel and dried in a desiccator at room temperature (connected to air pump) until constant weight to yield carvedilol Form IV.
Example 15:
Preparation of Crystalline Carvedilol Form V .
Carvedilol (1g) was dissolved in 70 mL methyl ethyl ketone by stirnng at room temperature, and 138 mL hexane were added dropwise. The solution was left at room temperature without stirnng for about 15h, then the resulting crystals were filtered through a buchner funnel and dried in a desiccator at room temperature (connected to air pump) until constant weight to yield carvedilol Form V.

Example 16:
Preparation of Crystalline Carvedilol Form V .
Carvedilol (2g) was dissolved in 45 mL methyl ethyl ketone by heating the mixture under stirring at SS °C water bath, then the solution was cooled and left at room temperature without stirring for about 14 hours, the crystals were filtered through a buchner funnel and dried in a desiccator at room temperature (connected to air pump) until constant weight to yield carvedilol Form V.

Claims (82)

1. A process for preparing carvedilol comprising a step of reacting a compound of formula II, 4-(oxiran-2-ylmethoxy)-9H-carbazole, with a compound of formula III, 2-(2-methoxyphenoxy)ethylamine wherein the compound of formula III is at a molar excess over the compound of formula II.
2. The process of claim 1, wherein the compound of formula III and the compound of formula II are at a molar ratio from about 1.5:1 to about 100:1.
3. The process of claim 1, wherein the compound of formula III and the compound of formula II are at a molar ratio from about 2.8:1 to about 10:1.
4. The process of claim 1, wherein the compound of formula III and the compound of formula II are at a molar ratio from about 2.8:1 to about 6:1.
5. The process of claim 1, wherein the reacting step is performed in a solvent.
6. The process of claim 5, wherein the solvent is selected from the group consisting of toluene, xylene and heptane.
7. The process of claim 1, wherein the reacting step is performed in a solvent mixture wherein the solvent mixture comprises multiple solvents.
8. The process of claim 7, wherein a solvent of the solvent mixture is selected from the group consisting of toluene, xylene and heptane.
9. The process of claim 1, wherein the reacting step is performed at a temperature from about 25°C to about 150°C.
10. The process of claim 1, wherein the reacting step is performed at a temperature from about 60°C to about 120°C.
11. The process of claim 1, wherein the reacting step is performed under neat conditions.
12. The process of claim 11, wherein the neat conditions are obtained by melting a solid form of the compound of formula III to form a liquid and, dissolving the compound of formula II in the liquid to form a reaction mixture.
13. The process of claim 11, further comprising a step of reducing the temperature of the reaction mixture after dissolving the compound of formula II.
14. The process of claim 13, wherein the temperature is reduced to about 70°C.
15. The process of claim 11, further comprising a step of adding an organic solvent:

water mixture to the reaction mixture.
16. The process of claim 15, wherein the organic solvent is selected from the group consisting of ethyl acetate, butyl acetate and methyl ethyl ketone.
17. The process of claim 15, further comprising a step of adjusting the pH of the organic solvent: water mixture to the reaction mixture after the organic solvent:

water mixture is added to the reaction mixture.
18. The process of claim 17, wherein the pH is adjusted to less than about pH
5.
19. The process of claim 17, wherein the pH is adjusted from about pH 3 to about pH
5.
20. The process of claim 11, further comprising steps of:

a) isolating carvedilol hydrochloride after adjusting the pH, and b) purifying carvedilol.
21. The process of claim 20, wherein carvedilol hydrochloride is a hydrate.
22. Crystalline carvedilol hydrate.
23. Crystalline carvedilol.
24. Crystalline carvedilol (methyl-ethyl-ketone) solvate.
25. Crystalline carvedilol Form III.
26. The crystalline carvedilol of claim 25, characterized by an X-ray powder diffraction pattern having peaks at about 8.4 ~ 0.2, 17.4 ~ 0.2, and 22.0 ~ 0.2 degrees two-theta.
27. The carvedilol of claim 26, further characterized by an X-ray powder diffraction pattern having peaks at about 9.3 ~ 0.2, 11.6 ~ 0.2, 13.2 ~ 0.2, 13.5 ~ 0.2, 14.2 ~
0.2, 15.3~0.2, 15.8~0.2, 18.4~0.2, 19.4~0.2,20.6~0.2,21.4~0.2,26.5~0.2 and 27.6 ~ 0.2 degrees two-theta.
28. The crystalline carvedilol of claim 24, characterized by a water content of about 2.0 by weight.
29. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline carvedilol of claim 24, and a pharmaceutically acceptable carrier.
30. A method for treating a patient suffering from congestive heart failure by administering a therapeutically effective amount of crystalline carvedilol Form III.
31. A method for treating a patient suffering from hypertension by administering a therapeutically effective amount of crystalline carvedilol Form III.
32. Crystalline carvedilol Form IV.
33. The crystalline carvedilol of claim 32, characterized by an X-ray powder diffraction pattern having peaks at about 11.9 ~ 0.2, 14.2 ~ 0.2, 18.3 ~ 0.2, 19.2 ~ 0.2, 21.7 ~
0.2, and 24.2 ~ 0.2 degrees two-theta.
34. The crystalline carvedilol of claim 33, further characterized by an X-ray powder diffraction pattern having peaks at about 15.7 ~ 0.2, 16.5 ~ 0.2, 17.7 ~ 0.2, 19.6 ~
0.2, 22.2 ~ 0.2, 23.9 ~ 0.2, 24.9 ~ 0.2, 27.4 ~ 0.2 and 28.2 ~ 0.2 degrees two-theta.
35. Crystalline carvedilol (methyl-ethyl-ketone) solvate Form V.
36. The crystalline carvedilol of claim 35, characterized by an X-ray powder diffraction pattern having peaks at about 4.1 ~ 0.2, 10.3 ~ 0.2, and 10.7 ~ 0.2 degrees two-theta.
37. The crystalline carvedilol of claim 36, further characterized by an X-ray powder diffraction pattern having peaks at about 11.5 ~ 0.2, 12.6 ~ 0.2, 14.0 ~ 0.2, 14.8 ~
0.2, 15.4~0.2, 16.4~0.2, 16.8~0.2, 18.8~0.2,20.8~0.2,21.1~0.2,21.6~
0.2, and 25.4 ~ 0.2 degrees two-theta.
38. The crystalline carvedilol of claim 35, characterized by a methyl-ethyl-ketone content of about 14% by weight.
39. Carvedilol HCl Hydrate.
40. The crystalline carvedilol of claim 39, characterized by an X-ray powder diffraction pattern having peaks at about 6.5~0.2, 10.2~0.2, 10.4~0.2, 15.8~0.2,16.4~
0.2 and 22.2~0.2 degrees two-theta.
41. The crystalline carvedilol of claim 40, further characterized by an X-ray powder diffraction pattern having peaks at about 14.2~0.2, 14.7~0.2, 16.4~0.2, 17.7~
0.2, 20.0~0.2, 21.5~0.2, 21.9~0.2, 22.9~0.2, 25.2~0.2, 25.3~0.2, 27.2~
0.2, 27.4~0.2, 28.2~0.2, 28.6~0.2, 29.6~0.2 degrees two theta.
42. The crystalline carvedilol of claim 39 characterized by a water content of about 3.5% by weight.
43. A method for preparing crystalline carvedilol Form I, comprising the steps of:

a) dissolving carvedilol in a solution by heating;
b) heating the solution until the crystalline carvedilol is completely dissolved;
c) reducing the temperature of the solution;
d) agitating the solution for a period of time;
d) further reducing the temperature of the solution;
e) further agitating the solution for a period of time; and, e) collecting crystalline carvedilol Form I.
44. The method of claim 43, wherein the dissolving step is performed by heating the solution to about 77°C.
45. The method of claim 43, wherein the step of reducing the temperature of the solution is performed by cooling the solution to about 50°C in a time period of about 15 min.
46. The method of claim 43, wherein the step of agitating the solution is performed at about 50°C for about 48 hours.
47. The method of claim 43, wherein the step of further reducing the temperature of the solution is performed by cooling the solution to about 10°C in about 0.75 hours with agitation.
48. The method of claim 43, wherein the step of further agitating the solution is performed by stirring the suspension for more than about 5 hours.
49. A method for preparing crystalline carvedilol Form II, comprising the steps of:

a) forming a solution of carvedilol by dissolving carvedilol in a solvent;
b) precipitating carvedilol Form II by cooling the solution; and, c) isolating crystalline carvedilol Form II.
50. The process of claim 49, wherein the temperature is from about 40°C
to about the boiling temp of the solvent.
51. The process of claim 49, wherein the precipitated carvedilol Form II is isolated by filtration.
52. The process of claim 49, wherein the solution is cooled to a temperature from about -20°C to ambient temperature.
53. The process of claim 49, wherein the solvent is selected from the group consisting of methanol, ethanol, 1-propanol, isopropanol, n-butanol, ethylene glycol, butyl acetate, isobutyl methyl ketone, dichloromethane, dichloroethane, acetonitrile, acetone, isoamylalcohol, xylene and toluene.
54. A method for preparing crystalline carvedilol Form II, comprising the steps of:

a) forming a solution of carvedilol by dissolving carvedilol in a solvent mixture;
b) precipitating carvedilol Form II by cooling the solution to about -20°C; and, c) isolating crystalline carvedilol Form II.
55. The process of claim 54, wherein the temperature of the solution is from about 40°C to about the boiling temperature of the solvent.
56. The process of claim 54, wherein the precipitated carvedilol Form II is isolated by filtration.
57. The process of claim 54, wherein the solution is cooled to a temperature from about -20°C to ambient temperature.
58. The method of claim 54, wherein the solvent mixture is selected from the group consisting of acetone: cyclohexane, chloroform: cyclohexane, dichloroethane:

cyclohexane, dichloromethane: cyclohexane, pyridine: cyclohexane, tetrahydrofurane:cyclohexane, dioxane: cyclohexane, acetone: hexane, chloroform:
hexane, dichloroethane: hexane, dichloromethane: hexane, tetrahydrofuran:
hexane and ethanol: hexane.
59. A method for preparing crystalline carvedilol Form III, comprising the steps of:

a) dissolving carvedilol in a solvent to form a solvent solution; and, b) precipitating crystalline carvedilol Form III from the solvent solution using water as an anti-solvent.
60. The method of claim 59, wherein water is present in the solvent solution during the dissolving step.
61. The method of claim 59, wherein the precipitation step is performed by adding water to the solution after carvedilol is fully dissolved in the solvent.
62. The method of claim 59, wherein the dissolving step is performed at elevated temperature.
63. The method of claim 59, wherein the elevated temperature is from about 40°C to about 90°C.
64. The method of claim 59, wherein the elevated temperature is about 55°C.
65. The method of claim 59, wherein the dissolving step is performed at ambient temperature.
66. The method of claim 59, wherein the solvent is selected from the group consisting of pyridine, dioxane, methanol, ethanol, isopropanol and chloroform.
67. The method of claim 59, wherein the solvent consists of a mixture of solvents.
68. A method for preparing crystalline carvedilol Form IV, comprising the steps of:

a) dissolving carvedilol in a solvent to form a solvent solution;
b) adding an anti-solvent to the solvent solution; and, c) precipitating crystalline carvedilol Form IV from the solvent solution.
69. The method of claim 68, wherein the solvent is methyl ethyl ketone.
70. The method of claim 68, wherein the anti-solvent is cyclohexane.
71. The method of claim 68, wherein the dissolving step is performed at from about 10°C to about 50°C.
72. The method of claim 68, wherein the dissolving step is performed at about 55°C.
73. The method of claim 68, wherein the dissolving step is performed at ambient temperature.
74. A method for preparing crystalline carvedilol Form V, comprising the steps of:

a) dissolving carvedilol in a solvent to form a solvent solution; and, b) precipitating and isolating crystalline carvedilol Form V from the solvent solution.
75. The method of claim 74, wherein the solvent is methyl ethyl ketone.
76. The method of claim 74, wherein the dissolving step is performed by dissolving carvedilol at ambient temperature.
77. The method of claim 74, wherein the temperature of dissolution is from about 10°C
to about 80°C.
78. The process of claim 74, wherein carvedilol Form V is precipitated by cooling.
79. A method for preparing crystalline carvedilol Form V, comprising the steps of:

a) dissolving carvedilol in a solvent to form a solvent solution; and, b) precipitating and isolating crystalline carvedilol Form V from the solvent solution wherein the precipitation step is performed by adding an anti-solvent.
80. The method of claim 79, wherein the solvent is methyl ethyl ketone.
81. The method of claim 79, wherein the dissolving step is performed by dissolving carvedilol at ambient temperature.
82. The method of claim 79, wherein the of anti-solvent is hexane.
CA 2413702 2000-06-28 2001-06-28 Carvedilol Abandoned CA2413702A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US21435600 true 2000-06-28 2000-06-28
US60/214,356 2000-06-28
US24635800 true 2000-11-07 2000-11-07
US60/246,358 2000-11-07
PCT/US2001/020760 WO2002000216A1 (en) 2000-06-28 2001-06-28 Carvedilol

Publications (1)

Publication Number Publication Date
CA2413702A1 true true CA2413702A1 (en) 2002-01-03

Family

ID=26908910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2413702 Abandoned CA2413702A1 (en) 2000-06-28 2001-06-28 Carvedilol

Country Status (7)

Country Link
US (6) US6699997B2 (en)
JP (1) JP2004501191A (en)
KR (3) KR20080064908A (en)
CN (1) CN1245974C (en)
CA (1) CA2413702A1 (en)
EP (1) EP1299101A4 (en)
WO (1) WO2002000216A1 (en)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245974C (en) 2000-06-28 2006-03-22 特瓦制药工业有限公司 Carvedilol
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
DE60220678T2 (en) * 2001-08-13 2008-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of the aggregation of polyQ
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
WO2003029214A1 (en) * 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DE10156894A1 (en) * 2001-11-20 2003-05-28 Bayer Ag New ureido-substituted pyrrolidine-dione derivatives, useful in human or veterinary medicine as broad-spectrum antibacterial agents
US20030171411A1 (en) * 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
KR20040077872A (en) * 2002-01-15 2004-09-07 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline solids of carvedilol and processes for their preparation
US20050148779A1 (en) * 2002-04-30 2005-07-07 Wei Chen Carvedilol monocitrate monohydrate
EP1501502A2 (en) * 2002-05-03 2005-02-02 SmithKline Beecham Pharmco Puerto Rico, Inc. Carvedilol pharmasolve solvate
WO2003101981A1 (en) * 2002-05-30 2003-12-11 Astrazeneca Ab Novel substituted indoles
CN103288715A (en) 2002-06-27 2013-09-11 史密斯克莱.比奇曼(科克)有限公司 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
JP4881559B2 (en) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー/エス Arylcarbonyl derivatives as therapeutic agents
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
JP4597667B2 (en) * 2002-07-15 2010-12-15 ヘルムホルツ ツェントラム フュア インフェクションズフォルシュング ゲーエムベーハー(ハーツェットイー)Gesellschaft fuer Biotechnologische Forschung mbh (GBF) New macro cycle for cancer treatment
WO2004007451A1 (en) * 2002-07-17 2004-01-22 Astrazeneca Ab Indole-3-sulphur derivatives
EP1543012B1 (en) * 2002-08-21 2008-07-16 AstraZeneca AB 6h-thien 2, 3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh)
US20070142437A1 (en) * 2005-04-08 2007-06-21 Brown Matthew L Chemical compounds
WO2004041783A1 (en) * 2002-11-08 2004-05-21 Zentiva, A.S. Process for preparation of carvedilol
ES2330517T3 (en) * 2002-11-28 2009-12-11 Wolfgang Richter Tia-epothilone derivatives for the treatment of cancer.
WO2004052862A1 (en) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
US20060166983A1 (en) * 2003-01-06 2006-07-27 Eli Lilly And Company Indole derivatives as ppar modulators
JP2006516572A (en) * 2003-01-14 2006-07-06 アリーナ ファーマシューティカルズ, インコーポレイテッド Prevention and treatment of disorders such as 1,2,3-trisubstituted aryl derivatives as metabolic modulators and 1,2,3 substituted heteroaryl derivatives and diabetes and hyperglycemia associated with these derivatives
JP4588018B2 (en) * 2003-04-07 2010-11-24 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Novel compounds
DK1611091T3 (en) * 2003-04-07 2015-01-05 Astrazeneca Ab Substituted phenylalkansyrederivater and their use for the treatment of respiratory diseases
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
WO2004094378A1 (en) 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
CN1826310B (en) * 2003-07-24 2010-07-21 利奥制药有限公司 Novel aminobenzophenone compounds
JP2007501836A (en) * 2003-08-13 2007-02-01 クドス ファーマシューティカルズ リミテッド Its use as Aminopiron acids and atm inhibitors
DE602004020356D1 (en) 2003-08-21 2009-05-14 Astrazeneca Ab Phenoxyessigsäurederivate
EP1660451A2 (en) * 2003-09-02 2006-05-31 KRKA, tovarna zdravil, d.d., Novo mesto New crystalline forms of carvedilol
WO2005035495B1 (en) * 2003-10-08 2005-09-29 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
DE602004001134T2 (en) * 2003-10-31 2007-04-19 Arena Pharmaceuticals, Inc., San Diego Tetrazole derivatives and process for the treatment of metabolic diseases in order
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005051325A3 (en) * 2003-11-25 2005-08-11 Matthew D Burke Carvedilol compositions methods of treatment and delivery
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
ES2399052T3 (en) 2004-01-06 2013-03-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
WO2005080329A3 (en) * 2004-02-23 2006-09-28 Virendra Kumar Agarwal Process for manufacture of racemic carvedilol
JP2007531755A (en) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap Non imidazole heterocycles
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
CN1946703A (en) * 2004-04-20 2007-04-11 特兰斯泰克制药公司 Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
CA2564030C (en) * 2004-05-05 2010-06-08 Pfizer Products Inc. Salt forms of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
CA2569111A1 (en) * 2004-06-02 2005-12-22 Schering Corporation Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
US20070167426A1 (en) * 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418613D0 (en) * 2004-08-20 2004-09-22 Pugh Rhoderick Internet security system
GB0418830D0 (en) * 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
JP2008513428A (en) * 2004-09-20 2008-05-01 キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited Dna-pk inhibitors
US8268789B2 (en) * 2004-09-30 2012-09-18 Kowa Company, Ltd. PAR-2 antagonists
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
EP1802591B1 (en) * 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
CA2582933A1 (en) * 2004-10-14 2006-04-20 Euro-Celtique S.A. 4-phenylsulfonamidopiperidines as calcium channel blockers
DE102004051023A1 (en) * 2004-10-20 2006-05-04 Bayer Healthcare Ag Deoxo-nonadepsipeptides
DE102004051025A1 (en) * 2004-10-20 2006-04-27 Bayer Healthcare Ag substituted nonadepsipeptides
DE102004051024A1 (en) * 2004-10-20 2006-04-27 Bayer Healthcare Ag Heterocyclyl-substituted nonadepsipeptides
DE102004053410A1 (en) * 2004-11-05 2006-05-11 Bayer Healthcare Ag cyclic Nonadepsipeptidamide
EP1828099A1 (en) * 2004-11-18 2007-09-05 Cardimone Pharma Corporation Synthetic process for aminocyclohexyl ether compounds
DK1817282T3 (en) * 2004-11-23 2011-10-10 Astrazeneca Ab For the treatment of respiratory diseases suitable phenoxy derivative
CA2589483C (en) * 2004-12-03 2013-10-29 Schering Corporation Substituted piperazines as cb1 antagonists
CN100591668C (en) * 2004-12-09 2010-02-24 Zach系统股份公司 Process for the preparation of carvedilol and its enantiomers
US7385028B2 (en) * 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
WO2006070780A1 (en) * 2004-12-28 2006-07-06 Kowa Company, Ltd. Par-2 agonist
EP1848712A1 (en) * 2005-02-09 2007-10-31 Kudos Pharmaceuticals Ltd Atm inhibitors
US20060264623A1 (en) * 2005-04-15 2006-11-23 Kudos Pharmaceuticals Limited DNA-PK inhibitors
JP2008535902A (en) * 2005-04-15 2008-09-04 キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited Dna-pk inhibitors
US7816405B2 (en) * 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
US20080287396A1 (en) * 2005-04-21 2008-11-20 Targanta Therapeutica Inc. Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections
EP2172452A1 (en) * 2005-05-03 2010-04-07 Ranbaxy Laboratories Limited Preparation of crystalline atorvastatin magnesium
KR20070088507A (en) * 2005-06-09 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline forms of carvedilol and processes for their preparation
EP1915340B1 (en) * 2005-06-15 2013-08-07 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
US8343928B2 (en) * 2005-07-07 2013-01-01 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
ES2382815T3 (en) * 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas as glucokinase activators
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
US7851474B2 (en) * 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
CA2617788A1 (en) * 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
EP1909846A2 (en) * 2005-08-05 2008-04-16 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
JP2009506096A (en) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー Liquid preparations pegylated growth hormone
EP1928409B1 (en) 2005-09-12 2012-09-12 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
DE602006015984D1 (en) 2005-10-06 2010-09-16 Astrazeneca Ab Biphenyloxyessigsäurederivate for treatment of airway diseases
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
JP2009514935A (en) * 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Novel compounds
DK1954710T3 (en) * 2005-11-08 2011-06-27 Ambrx Inc To accelerate the modification of unnatural amino acids and unnatural aminosyrepolypeptider
DE602006019905D1 (en) * 2005-11-15 2011-03-10 Neves Da Silva Ruas Da Silva Maria Do Carmo N metal salts for medical use
US7714014B2 (en) * 2005-12-09 2010-05-11 The Regents Of The University Of California Targeting GLI proteins in human cancer by small molecules
WO2007070564A3 (en) * 2005-12-13 2008-08-07 Harkness Pharmaceuticals Inc Methods of treating obesity using enterostatin
WO2007070562A3 (en) * 2005-12-13 2008-11-27 Harkness Pharmaceuticals Inc Non-hygroscopic compositions of enterostatin
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
CA2631491C (en) 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP2305640A3 (en) * 2005-12-15 2011-07-20 AstraZeneca AB Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
WO2007077111A1 (en) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Compounds and methods for carbazole synthesis
US8975404B2 (en) * 2006-01-24 2015-03-10 Dh Technologies Development Pte. Ltd. Labeling reagents for analyte determination and methods and compounds used in making the same
DE102006003443A1 (en) * 2006-01-25 2007-07-26 Aicuris Gmbh & Co. Kg New lysobactin derivatives useful for treating bacterial infections in humans and animals
KR100746455B1 (en) * 2006-02-23 2007-07-30 안국약품 주식회사 Process for the preparation of highly optical pure carvedilol
CA2643826A1 (en) * 2006-02-27 2008-06-12 Paul A. Wender Compositions and methods for transport of molecules with enhanced release properties across biological barriers
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
JP2009530382A (en) * 2006-03-23 2009-08-27 シェーリング コーポレイションSchering Corporation Combination of Hcv protease inhibitors and cyp3a4 inhibitor, and related methods of treatment
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
EP2181993A1 (en) 2006-03-31 2010-05-05 Research Foundation Itsuu Laboratory Antimicrobial oxazolidinone derivatives
US8937181B2 (en) * 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
DE102006018250A1 (en) * 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg A process for preparing cyclic depsipeptides
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
DE102006018080A1 (en) * 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Lysobactinamide
CN101437800A (en) * 2006-05-05 2009-05-20 Irm责任有限公司 Compounds and compositions as HEDGEHOG pathway modulators
US7683043B2 (en) * 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
WO2007146086A1 (en) * 2006-06-06 2007-12-21 Xenoport, Inc. Creatine prodrugs, compositions and uses thereof
US20070281983A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine analog prodrugs, compositions and uses thereof
US20070281909A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine phosphate prodrugs, compositions and uses thereof
US20070281910A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Salicyl alcohol creatine phosphate prodrugs, compositions and uses thereof
EP1991527A2 (en) * 2006-06-28 2008-11-19 Teva Pharmaceutical Industries Ltd Polymorphous forms of carvedilol phosphate
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
JP5252458B2 (en) * 2006-07-07 2013-07-31 ノボ ノルディスク ヘルス ケア アーゲー Novel protein conjugate and a method of manufacturing the same
US8759342B2 (en) * 2006-07-31 2014-06-24 Janssen Pharmaceutica Nv Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists
CN104906087A (en) * 2006-09-13 2015-09-16 万能医药公司 Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
GB2442238B (en) * 2006-09-29 2008-10-01 Rolls Royce Plc Sheet metal blank
CA2667857A1 (en) * 2006-10-30 2008-05-08 Biovitrum Ab (Publ) 8-sulfonyl-1, 3, 4, 8-tetrahydr0-2h- [1, 4] oxazepino [6, 7-e] indole derivatives and their use as 5-ht6 receptor ligands
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
DE102007026550A1 (en) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudates having improved taste masking
CN101796042B (en) * 2007-07-05 2013-05-08 阿斯利康(瑞典)有限公司 Novel compounds 951: a biphenyloxypropanoic acid as CRTH2 modulator and intermediates
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
US20090042865A1 (en) * 2007-07-19 2009-02-12 Mark Frigerio Dna-pk inhibitors
JP5323075B2 (en) 2007-08-17 2013-10-23 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 4-pyrimidin-sulfamide derivatives
EP2195292B1 (en) 2007-08-21 2013-10-02 Lupin Ltd. Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
FR2927809B1 (en) * 2008-02-26 2011-01-14 Tri Inov New use of zinc n-acetyl-taurinate.
WO2009111688A3 (en) * 2008-03-06 2009-12-10 Wisconsin Alumni Research Foundation All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof
ES2524883T3 (en) * 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-hydroxypyrimidine-5-carboxamides
WO2009115902A1 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Process for the preparation of carvedilol via silyl protection of substituted amine
US9023809B2 (en) * 2008-03-27 2015-05-05 The Key Laboratory Of Chemistry For Natural Products Of Guizhou Province And Chinese Academy Of Sciences Phenylalanine dipeptide derivatives, compositions and use thereof
JP5770629B2 (en) 2008-08-15 2015-08-26 アイアンウッド ファーマシューティカルズ インコーポレイテッド Stable solid formulations suitable gc-c receptor agonist polypeptide oral administration
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
US20110229438A1 (en) * 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US20100197567A1 (en) * 2008-10-17 2010-08-05 University Of Utah Research Foundation Conus polypeptides
EP2346524A2 (en) * 2008-11-20 2011-07-27 Merck Patent GmbH New therapy and medicament using integrin ligands for treating cancer
WO2010060901A1 (en) * 2008-11-25 2010-06-03 Novo Nordisk A/S Peptides for treatment of obesity
JP2013504581A (en) * 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッドSunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and their use
RU2011137419A (en) 2009-02-11 2013-03-20 Суновион Фармасьютикалз Инк. Inverse agonists and antagonists of histamine H3 and methods for their use
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US20130203861A1 (en) * 2009-09-09 2013-08-08 Golden Biotechnology Corporation Methods and compositions for treating ovarian cancer
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CN102190613B (en) * 2010-03-14 2014-06-25 浙江华海药业股份有限公司 Method for preparing carvedilol
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
US9102712B2 (en) * 2010-08-27 2015-08-11 New York University Dendrimeric peptides, pharmaceutical compositions and methods of using the same
CN103415531B (en) * 2011-02-09 2016-10-26 器官平衡有限责任公司 Peptides for the treatment of skin disorders
CN104053449B (en) 2011-08-17 2016-12-07 硬木药品公司 Gastrointestinal disorders treatment
EP2825534A1 (en) * 2012-03-16 2015-01-21 Sandoz AG Process for the synthesis of telaprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof
WO2013162729A1 (en) 2012-04-24 2013-10-31 The Board Of Trustees Of The Leland Stanford Junior University Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
WO2014075146A1 (en) * 2012-11-16 2014-05-22 Adelaide Research & Innovation Pty Ltd Macrocyclic compounds and uses thereof
WO2014118180A1 (en) * 2013-01-30 2014-08-07 Sandoz Ag Crystalline form of linaclotide
EP3003352A1 (en) * 2013-05-31 2016-04-13 Centre National de la Recherche Scientifique (CNRS) Protein involved in dna replication, and modulation of its activity
WO2015003816A3 (en) * 2013-07-12 2015-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
US20160214973A1 (en) * 2013-08-30 2016-07-28 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same
CN104592096A (en) * 2014-12-24 2015-05-06 江苏苏南药业实业有限公司 Preparation method for S-carvedilol

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (en) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh New carbazolyl (4) -oxy-propanolamine derivatives, processes for their preparation and medicines containing compounds
DE3319027A1 (en) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh A process for the preparation of optically active carbazole derivatives, new R- and S-carbazole derivatives, and pharmaceutical compositions containing these compounds
FR2725623B1 (en) 1994-10-18 1997-02-21
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
EP0893440A1 (en) * 1997-07-22 1999-01-27 Boehringer Mannheim Gmbh Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
DE69813729D1 (en) * 1997-11-24 2003-05-28 Egyt Gyogyszervegyeszeti Gyar A process for preparing 1- (9'H-carbazol-4'yloxy) -3-2 '' - (2 '' '- methoxy-phenoxy) ethyl) -amino) -2-ol (Carvedilol) and intermediate compounds
DE19954569A1 (en) 1999-11-12 2001-05-17 Schwabe Willmar Gmbh & Co Pharmacologically active tetrahydrothiopyran-4-ol derivatives, processes for their preparation and use
WO2001066702A1 (en) 2000-03-08 2001-09-13 Ira Istituto Ricerche Applicate S.R.L. Cosmetic or pharmaceutical composition useful in inhibiting or delaying human alopecia by means of topical application of the composition
CN1245974C (en) 2000-06-28 2006-03-22 特瓦制药工业有限公司 Carvedilol
US6365618B1 (en) 2000-12-13 2002-04-02 Conrad M. Swartz Administration of carvedilol to mitigate tardive movement disorders, psychosis, mania, and depression
CN1266131C (en) 2001-01-25 2006-07-26 弗·哈夫曼-拉罗切有限公司 Process for the preparation of heterocgclic indene analogs
EP1406614B1 (en) 2001-07-13 2006-06-07 Smithkline Beecham Corporation Carvedilol polymorph
US20040152756A1 (en) 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
WO2003029214A1 (en) 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
KR20040077872A (en) 2002-01-15 2004-09-07 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline solids of carvedilol and processes for their preparation
CN103288715A (en) 2002-06-27 2013-09-11 史密斯克莱.比奇曼(科克)有限公司 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
WO2004041783A1 (en) 2002-11-08 2004-05-21 Zentiva, A.S. Process for preparation of carvedilol
WO2004094378A1 (en) 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
WO2004113296A1 (en) 2003-06-20 2004-12-29 Sun Pharmaceutical Industries Limited A process for preparation of 1-[9h-carbazol-4-yloxy]- 3-[{2-(2-(-(methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
EP1660451A2 (en) 2003-09-02 2006-05-31 KRKA, tovarna zdravil, d.d., Novo mesto New crystalline forms of carvedilol
WO2005051383A1 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
WO2005080329A3 (en) 2004-02-23 2006-09-28 Virendra Kumar Agarwal Process for manufacture of racemic carvedilol
US20070191456A1 (en) 2004-04-22 2007-08-16 Tarur Venkatasubramanian R Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol
GB0411273D0 (en) 2004-05-20 2004-06-23 Cipla Ltd Process and product
CN100591668C (en) 2004-12-09 2010-02-24 Zach系统股份公司 Process for the preparation of carvedilol and its enantiomers
US20070027202A1 (en) 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
WO2007057316A3 (en) 2005-11-16 2007-07-05 Hoffmann La Roche Novel process for the preparation of thoc
WO2007077111A1 (en) 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Compounds and methods for carbazole synthesis
KR100746455B1 (en) 2006-02-23 2007-07-30 안국약품 주식회사 Process for the preparation of highly optical pure carvedilol

Also Published As

Publication number Publication date Type
US20080194838A1 (en) 2008-08-14 application
US20040152757A1 (en) 2004-08-05 application
WO2002000216A1 (en) 2002-01-03 application
US7056942B2 (en) 2006-06-06 grant
US6699997B2 (en) 2004-03-02 grant
KR20080015888A (en) 2008-02-20 application
EP1299101A4 (en) 2004-06-16 application
US20020143045A1 (en) 2002-10-03 application
US7605274B2 (en) 2009-10-20 grant
US20040225132A1 (en) 2004-11-11 application
KR20030017569A (en) 2003-03-03 application
EP1299101A1 (en) 2003-04-09 application
US7126008B2 (en) 2006-10-24 grant
KR20080064908A (en) 2008-07-09 application
CN1245974C (en) 2006-03-22 grant
US7485663B2 (en) 2009-02-03 grant
US20060030614A1 (en) 2006-02-09 application
US20090326033A1 (en) 2009-12-31 application
JP2004501191A (en) 2004-01-15 application
CN1449286A (en) 2003-10-15 application

Similar Documents

Publication Publication Date Title
US20080058355A1 (en) Crystalline erlotinib
WO2001032601A1 (en) Polymorphic forms of sertraline hydrochloride
WO2006054314A1 (en) Polymorphic forms of imatinib mesylate
US20030166702A1 (en) Crystalline solids of carvedilol and processes for their preparation
US7183272B2 (en) Crystal forms of oxcarbazepine and processes for their preparation
US20020077332A1 (en) Zolpidem hemitartrate
WO2011004392A1 (en) Crystalline form of prasugrel hydrobromide, preparation and application thereof
US20040010151A1 (en) Lansoprazole polymorphs and processes for preparation thereof
WO2009098142A1 (en) Prasugrel salts with improved properties
WO2005058819A2 (en) Polymorphic forms of tegaserod base and salts thereof
US20040009989A1 (en) Novel crystalline forms of gatifloxacin
US20040242661A1 (en) Polymorphs of valsartan
WO2004056804A2 (en) Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US20040030190A1 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride
US20040198812A1 (en) Pseudopolymorphic forms of carvedilol
US20040063782A1 (en) Bicalutamide forms
WO2010059913A2 (en) Preparation of rasagiline and salts thereof
CN101641345A (en) Imatinib base, and imatinib mesylate and processes for preparation thereof
WO2009130604A2 (en) Solid state forms of deferasirox salts and process for the preparation thereof
US20060258677A1 (en) Novel crystalline forms of gatifloxacin and processes for preparation
US7056942B2 (en) Carvedilol
US20070293702A1 (en) Novel crystalline forms of armodafinil and preparation thereof
US20030225129A1 (en) Polymorphs of clopidogrel hydrogensulfate
WO2008135795A2 (en) Polymorphic forms of bosentan
US20090105346A1 (en) Novel crystalline forms of armodafinil and preparation thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead